Evidence map›Paper›PMID 39066237›Full record

ArticleViruses2024

Comparative Evaluation of Select Serological Assays for Zika Virus Using Blinded Reference Panels.

Devy M Emperador, Mars Stone, Eduard Grebe, Camille Escadafal, Honey Dave, Eve Lackritz, Cassandra Kelly-Cirino, Ingrid Rabe, Diana P Rojas, Michael P Busch and 1 more

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Devy M EmperadorPandemic Threats Programme, Foundation for Innovative New Diagnostics (FIND), 1218 Geneva, Switzerland.ORCID 0000-0002-8228-1824
Mars StoneVitalant Research Institute, San Francisco, CA 94105, USA.ORCID 0000-0001-5619-2767
Eduard GrebeVitalant Research Institute, San Francisco, CA 94105, USA.ORCID 0000-0001-7046-7245
Camille EscadafalPandemic Threats Programme, Foundation for Innovative New Diagnostics (FIND), 1218 Geneva, Switzerland.ORCID 0000-0002-0268-750X
Honey DaveVitalant Research Institute, San Francisco, CA 94105, USA.
Eve LackritzEpidemic and Pandemic Preparedness and Prevention Department, Health Emergencies Programme, World Health Organization, 1211 Geneva, Switzerland.
Cassandra Kelly-CirinoPandemic Threats Programme, Foundation for Innovative New Diagnostics (FIND), 1218 Geneva, Switzerland.ORCID 0000-0002-4526-8487
Ingrid RabeEpidemic and Pandemic Preparedness and Prevention Department, Health Emergencies Programme, World Health Organization, 1211 Geneva, Switzerland.
Diana P RojasEpidemic and Pandemic Preparedness and Prevention Department, Health Emergencies Programme, World Health Organization, 1211 Geneva, Switzerland.ORCID 0000-0003-0241-6416
Michael P BuschVitalant Research Institute, San Francisco, CA 94105, USA.ORCID 0000-0002-1446-125X
Graham SimmonsVitalant Research Institute, San Francisco, CA 94105, USA.ORCID 0000-0002-9615-7023

Funding

Viral/Immune parameters of Dengue and WNV in donors: blood safety implicationsRC2HL101632 · NHLBI · VITALANT · PI BUSCH, MICHAEL PAUL · 2009 to 2010
$2.1M
CDC HHS 200-2014-M-59495CDC HHS 200-2015-M-81883NHLBI NIH HHS RC2 HL101632World Health Organization 001World Health Organization n/a
6 · The paper itself

Abstract

In response to the 2015 Zika virus (ZIKV) epidemic that occurred in Brazil, numerous commercial serological assays have been developed for clinical and research applications. Diagnosis of recent infection in pregnant women remains challenging. Having standardized, comparative studies of ZIKV tests is important for implementing optimal diagnostic testing and disease surveillance. This is especially important for serology tests used to detect ZIKV infection given that antibodies against ZIKV can cross-react with other arboviruses in the same virus family, such as dengue virus (DENV), yellow fever virus (YFV) and West Nile virus (WNV). We looked at the sensitivity and specificity of tests detecting ZIKV antibodies (IgM, IgG) from multiple manufacturers using panels of samples previously collected with known exposure to ZIKV and other arboviruses. We found that performance of the IgM tests was highly variable, with only one test (Inbios 2.0 IgM capture ELISA) having both high sensitivity and specificity. All IgG tests showed good sensitivity; however, specificity was highly variable, with some assays giving false-positive results on samples infected by another flavivirus. Overall, the results confirmed that accurate ZIKV antibody testing is challenging, especially in specimens from regions endemic for multiple other flaviviruses, and highlight the importance of available and suitable reference samples to evaluate ZIKV diagnostics.

Indexed as

Antibodies, ViralImmunoglobulin GImmunoglobulin MSensitivity and SpecificitySerologic TestsZika VirusZika Virus InfectionBrazilCross ReactionsEnzyme-Linked Immunosorbent AssayFemaleHumansPregnancyAntibodies, ViralImmunoglobulin GImmunoglobulin Mdengue virusdiagnosticsIgGIgMZika virus

Identifiers

PMID39066237
PMCPMC11281645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.